An interventional study of TransThoracic Echocardiography imaging in Cardiac Disease, Heart Failure and Cardiac Ischemia, sponsored by Philips Healthcare. Completed at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Philips Healthcare (part of Philips) · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.
Among the 448 studies in Heart Failure with a site in France, this one is the 214th largest by enrollment of the 282 interventional ones that give a count, is one of 30 that started in 2017, is one of 176 with no phase, and was the 248th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
University Hospital, Montpellier · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 70 · Phase 4 15
First in 1983; this study’s year is marked. 30 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 196 across the 282 interventional studies, 321 across the 161 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 448 have an industry lead sponsor. The 10 most frequent:
This study is registered under Philips Healthcare, one of the names counted as Philips. Under that name alone:
Philips Healthcare is the lead sponsor of 35 studies on the registry; none are open to participants now.
Philips has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
28 of the studies in Heart Failure with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
Add all 28 to your calendar (.ics) → With an account.
Among the 448 studies in Heart Failure with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study is a pilot study for evaluating a guidance system that aims to facilitate high-quality echocardiographic acquisitions.
The primary objective of this study is to assess the feasibility for non-expert users (medical professionals but non-certified sonographers) to acquire parasternal, apical and subcostal views of suitable quality by using an existing ultrasound device (CE-marked, available in the market) and an additional guidance system (software prototype + probe motion tracking device). Such a system will help the user to place the probe on the patient and provide guidance for optimal acquisition of parasternal, apical and subcostal views.
The secondary objective of this study is to assess the feasibility for non-expert users to reproduce a simple clinical protocol by using an existing ultrasound device and the same additional guidance system.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
This study's enrollment of 55 is below the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Philips Healthcare is the lead sponsor of 35 studies on the registry; none are open to participants now.
Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
Device: TransThoracic Echocardiography imaging
Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
Device: TransThoracic Echocardiography imaging
ultrasound scanning
Echocardiography acquisition score [in %] [Operator's outcome]
Composite measurement that characterizes the echocardiography acquisition of the operator who is being assessed with respect to a 2D reference acquisition The echocardiography acquisition score is a combination of the view type score and the image quality score
Time frame: Day 1
Time to acquisition [in seconds] [Operator's performance]
Time to acquisition \[in seconds\] to reach an echocardiography acquisition score of 25%, 50%, 75% and 90%
Time frame: Day 1
Displacement [in mm] of the echocardiography probe with respect to the 2D reference acquisition [Technical reproducibility]
Displacement \[in mm\] of the echocardiography probe at the acquisition time with respect to the 2D reference acquisition \[Reproducibility of the probe position and orientation\]
Time frame: Day 1
Displacement [in mm] of the echocardiography probe with respect to the ideal acquisition [Geometrical reliability]
Displacement \[in mm\] of the echocardiography probe at the acquisition time with respect to the ideal (geometrical) acquisition estimated from 3D reference acquisition \[Geometrical reliability of the probe position and orientation\]
Time frame: Day 1
Left ventricular Ejection Fraction [in %] [Measurement reproducibility]
Left ventricular Ejection Fraction \[in %\] by Simpson's biplane method
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Jan 2021, 37 months.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's 37 months is close to that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.